Key facts
- DoubleCHEK’s last known valuation is $8.3M (Nov 2025).
- It has raised $3.1M; the latest was Later Stage VC ($3.1M) in Nov 2025.
- Notable investors include British Business Bank, Puffin Point, British Design Fund, Freyr Investments, Namier Capital Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for DoubleCHEK
- ·The full record, as it builds
Funding rounds
No funding rounds for DoubleCHEK are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DoubleCHEK
Developer of medical devices designed to improve enteral access by enabling safer placement of nasogastric feeding and decompression tubes. The company offers a tube-compatible device with dual carbon dioxide and pH indicators, enabling clinicians working with infants to reduce misplacements, avoid lung insertion, and minimize unnecessary radiation exposure.
- Sector
- Healthcare
- HQ
- Liverpool, United Kingdom
- Founded
- 2018
- Employees
- 10
- Website
- enteralaccesstech.com/
- Ownership
- Privately Held (backing)
DoubleCHEK doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DoubleCHEK shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DoubleCHEK in its N-PORT filings yet. We sweep new filings monthly.